[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Siegel, R.L., Miller, K.D. and Jemal, A. (2019) Cancer Statistics, 2019. CA: A Cancer Journal for Clinicians, 69, 7-34.
https://doi.org/10.3322/caac.21551
|
[3]
|
Lehmann, B.D., Bauer, J.A., Chen, X., et al. (2011) Identification of Hu-man Triple-Negative Breast Cancer Subtypes and Preclinical Models for Selection of Targeted Therapies. Journal of Clinical Investigation, 121, 2750-2767.
https://doi.org/10.1172/JCI45014
|
[4]
|
Jiang, Y.Z., Ma, D., Suo, C., et al. (2019) Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell, 35, 428-440.e5.
|
[5]
|
Tomas, A., Futter, C.E. and Eden, E.R. (2014) EGF Receptor Trafficking: Consequences for Signaling and Cancer. Trends in Cell Biology, 24, 26-34. https://doi.org/10.1016/j.tcb.2013.11.002
|
[6]
|
Corkery, B., Crown, J., Clynes, M., et al. (2009) Epidermal Growth Factor Receptor as a Potential Therapeutic Target in Triple-Negative Breast Cancer. Annals of Oncology, 20, 862-867. https://doi.org/10.1093/annonc/mdn710
|
[7]
|
Linderholm, B.K., Hellborg, H., Johansson, U., et al. (2009) Significantly Higher Levels of Vascular Endothelial Growth Factor (VEGF) and Shorter Survival Times for Patients with Primary Operable Triple-Negative Breast Cancer. Annals of Oncology, 20, 1639-1646. https://doi.org/10.1093/annonc/mdp062
|
[8]
|
Zhu, X. and Zhou, W. (2015) The Emerging Regulation of VEGFR-2 in Triple-Negative Breast Cancer. Frontiers in Endocrinology, 6, Article No. 159. https://doi.org/10.3389/fendo.2015.00159
|
[9]
|
Brufsky, A.M., Hurvitz, S., Perez, E., et al. (2011) RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination with Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer. Journal of Clinical Oncology, 29, 4286-4293. https://doi.org/10.1200/JCO.2010.34.1255
|
[10]
|
Cameron, D., Brown, J., Dent, R., et al. (2013) Adjuvant Bevaci-zumab-Containing Therapy in Triple-Negative Breast Cancer (BEATRICE): Primary Results of a Randomised, Phase 3 Trial. The Lancet Oncology, 14, 933-942.
https://doi.org/10.1016/S1470-2045(13)70335-8
|
[11]
|
Jahan, N., Jones, C. and Rahman, R.L. (2021) Androgen Receptor Expression in Breast Cancer: Implications on Prognosis and Treatment, a Brief Review. Molecular and Cellular Endocrinology, 531, Article ID: 111324.
https://doi.org/10.1016/j.mce.2021.111324
|
[12]
|
Traina, T.A., Miller, K., Yardley, D.A., et al. (2018) Enzalutamide for the Treatment of Androgen Receptor-Expressing Triple-Negative Breast Cancer. Journal of Clinical Oncology, 36, 884-890.
https://doi.org/10.1200/JCO.2016.71.3495
|
[13]
|
Borsos, B.N., Páhi, Z.G., Ujfaludi, Z., et al. (2022) BC-miR: Monitoring Breast Cancer-Related miRNA Profile in Blood Sera—A Prosperous Approach for Tumor Detection. Cells, 11, Article No. 2721.
https://doi.org/10.3390/cells11172721
|
[14]
|
Hong, H.C., Chuang, C.H., Huang, W.C., et al. (2020) A Panel of Eight microRNAs Is a Good Predictive Parameter for Triple-Negative Breast Cancer Relapse. Theranostics, 10, 8771-8789. https://doi.org/10.7150/thno.46142
|
[15]
|
Clark, S.L., Rodriguez, A.M., Snyder, R.R., et al. (2012) Structure-Function of the Tumor Suppressor BRCA1. Computational and Structural Biotechnology Journal, 1, e201204005. https://doi.org/10.5936/csbj.201204005
|
[16]
|
Robson, M., Im, S.A., Senkus, E., et al. (2017) Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. New England Journal of Medicine, 377, 523-533. https://doi.org/10.1056/NEJMoa1706450
|
[17]
|
Duffy, M.J., Synnott, N.C. and Crown, J. (2018) Mutant p53 in Breast Cancer: Potential as a Therapeutic Target and Biomarker. Breast Cancer Research and Treatment, 170, 213-219. https://doi.org/10.1007/s10549-018-4753-7
|
[18]
|
Miricescu, D., Totan, A., Stanescu-Spinu, I.I., et al. (2020) PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects. Interna-tional Journal of Molecular Sciences, 22, Article No. 173.
https://doi.org/10.3390/ijms22010173
|
[19]
|
Kim, S.B., Dent, R., Im, S.A., et al. (2017) Ipatasertib plus Paclitaxel versus Placebo plus Paclitaxel as First-Line Therapy for Metastatic Triple-Negative Breast Cancer (LOTUS): A Multi-centre, Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial. The Lancet Oncology, 18, 1360-1372. https://doi.org/10.1016/S1470-2045(17)30450-3
|
[20]
|
Carter, J.M., Polley, M.Y.C., Leon-Ferre, R.A., et al. (2021) Characteristics and Spatially Defined Immune (Micro)landscapes of Early-Stage PD-L1-Positive Triple-Negative Breast Cancer. Clinical Cancer Research, 27, 5628-5637.
https://doi.org/10.1158/1078-0432.CCR-21-0343
|
[21]
|
Mittendorf, E.A., Zhang, H., Barrios, C.H., et al. (2020) Neoadjuvant Atezolizumab in Combination with Sequential Nab-Paclitaxel and Anthracycline-Based Chemotherapy ver-sus Placebo and Chemotherapy in Patients with Early-Stage Triple-Negative Breast Cancer (IMpassion031): A Random-ised, Double-Blind, Phase 3 Trial. The Lancet, 396, 1090-1100.
https://doi.org/10.1016/S0140-6736(20)31953-X
|
[22]
|
Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer (kConFab), Savas, P., Virassamy, B., et al. (2018) Single-Cell Profiling of Breast Cancer T Cells Reveals a Tissue-Resident Memory Subset Associated with Improved Prognosis. Nature Medicine, 24, 986-993. https://doi.org/10.1038/s41591-018-0078-7
|
[23]
|
Ibrahim, E.M., Al-Foheidi, M.E., Al-Mansour, M.M., et al. (2014) The Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: A Meta-Analysis. Breast Cancer Research and Treatment, 148, 467-476.
https://doi.org/10.1007/s10549-014-3185-2
|
[24]
|
Jaini, R., Kesaraju, P., Johnson, J.M., et al. (2010) An Autoim-mune-Mediated Strategy for Prophylactic Breast Cancer Vaccination. Nature Medicine, 16, 799-803. https://doi.org/10.1038/nm.2161
|
[25]
|
Amedei, A., Asadzadeh, F., Papi, F., et al. (2020) A Structurally Simple Vaccine Candidate Reduces Progression and Dissemination of Triple-Negative Breast Cancer. iScience, 23, Article ID: 101250.
https://doi.org/10.1016/j.isci.2020.101250
|
[26]
|
Bardia, A., Mayer, I.A., Vahdat, L.T., et al. (2019) Sacituzumab Govitecanhziy in Refractory Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 380, 741-751.
https://doi.org/10.1056/NEJMoa1814213
|
[27]
|
Bardia, A., Hurvitz, S.A., Tolaney, S.M., et al. (2021) Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 384, 1529-1541. https://doi.org/10.1056/NEJMoa2028485
|